News Bankruptcy threat looms as Quince runs out of options Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out.
News Lundbeck preps phase 3 for migraine prevention drug Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.
News PTC pulls file for Duchenne therapy on FDA feedback PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy treatment Translarna.
News BridgeBio gains on phase 3 dwarfism data Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.
News Euro VCs team up to invigorate life sciences ecosystem Major venture capital groups in Europe have joined forces to set up a new coalition aimed at revitalising access to life sciences investment.
News Zydus follows Lupin with Myrbetriq settlement deal Zydus has joined Lupin in agreeing to settle patent litigation with Astellas on its generic of big-selling overactive bladder drug Myrbetriq.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
